A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines. - Wikidata - wikimedia - TriplyDB

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.

http://www.wikidata.org/entity/Q33289806

about

Dendritic cells derived from pluripotent stem cells: Potential of large scale production Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation.Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects.Harnessing dendritic cells for tumor antigen presentation Dendritic cell-based cancer vaccination: quo vadis?Directing dendritic cell immunotherapy towards successful cancer treatment.Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.mRNA-based dendritic cell vaccines.Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice.In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells.Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties Multi-walled carbon nanotubes conjugated to tumor protein enhance the uptake of tumor antigens by human dendritic cells in vitro.Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer.

P2860

Q26865622-25C5844D-0753-4204-8531-51D1A59F21F2 Q33820274-2A279075-0E06-4ED9-9FBE-B6AA628B28B0 Q33921487-EB2D9110-5370-4FBC-96D9-C69B2370D79B Q34202646-76B84F9F-6558-4CF5-B2F8-0278FA28A233 Q34993170-14AF1BA7-FD7E-4DD0-9593-2F1281295103 Q35514419-370F3C03-8811-4500-80A7-2F49A366327F Q37132747-E9E47E10-9A4F-48F8-8460-DA78455FE580 Q37259624-7341ED9E-0D4F-43FD-962D-E3395717E4C3 Q37754014-AA4F8528-C803-4E18-83C3-E687E623D344 Q37773237-3AC072DD-34F9-450E-B048-F932A97B27E2 Q38059516-BFA1DF29-2DA1-42A1-8A08-18A9CFD43318 Q38246769-F283D873-21FC-40C9-A322-2BFD9854C0D8 Q39299639-851F7491-9F41-462E-8F9A-51778873DB22 Q39338676-AE36AC9C-18FC-49BA-A82C-2D91AEA6D7CA Q39775722-914E4885-72A3-40DC-AD3A-D488AD7EA17A Q40427880-D678D33D-16DC-473A-B737-D6A745EBED9C Q41945985-9FE189BC-4865-49B6-9DC7-D65C4E71C8F0 Q42908570-96161626-1AAD-4DA3-8F0B-CB946BABE375 Q49334976-926E87DC-FC83-4F86-A361-212E61A04246

P2860

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.

http://www.wikidata.org/entity/Q33289806

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

A full scale comparative study ...... ls for use as cancer vaccines.

@ast

A full scale comparative study ...... ls for use as cancer vaccines.

@en

A full scale comparative study ...... ls for use as cancer vaccines.

@nl

type

label

A full scale comparative study ...... ls for use as cancer vaccines.

@ast

A full scale comparative study ...... ls for use as cancer vaccines.

@en

A full scale comparative study ...... ls for use as cancer vaccines.

@nl

prefLabel

A full scale comparative study ...... ls for use as cancer vaccines.

@ast

A full scale comparative study ...... ls for use as cancer vaccines.

@en

A full scale comparative study ...... ls for use as cancer vaccines.

@nl

P1433

Q33289806-FE995C0B-B4C2-4A7C-B4AC-A3EF92BB9683

P1476

Q33289806-BBCF24A7-705B-40FB-9DAD-538C71515E30

P2093

Q33289806-147DF52E-B034-4E78-B0B5-6F9C2E41E586

Q33289806-1D7BD1A4-1F10-43E6-BB00-7FF40DF31769

Q33289806-3D9C7DE8-3CAB-4683-BA0C-E4F1B7124582

Q33289806-411F86B5-7846-4D87-9F8E-906378226DC2

P2860

Q33289806-02176698-6FCD-40D1-8D74-732A53A02400

Q33289806-2BAFC8F3-A2B4-4A9A-B233-FC5C51A469F7

Q33289806-2DB0D601-086C-4956-B4B2-BA415D4CF2C3

Q33289806-45D2A0AD-B3E2-4421-B39E-21D54AC4CDF9

Q33289806-6C3236AF-811E-4004-BB6B-C7439988666E

Q33289806-6ECEDF8D-4AD8-4619-9D0A-55B19B454245

Q33289806-84C15DEC-261A-47B2-9E44-2A96FAD9A09B

Q33289806-9F56A4A7-0AED-4E30-B887-118132689AEB

Q33289806-AB79F1C6-1974-4548-9FA5-F36F6E7545DC

Q33289806-BB2356B3-2DA7-4C38-898F-7D20AC0997F1

P2888

Q33289806-B284FE6D-4AB5-4DA5-A746-220FCBB5FE85

P304

Q33289806-7D86D49A-8D7C-4A75-AFBB-DE8D876E2A7A

P31

Q33289806-5923A68C-992E-4BF4-A3C0-006021037C07

P356

Q33289806-CA9EE040-024B-4EA3-BB95-18394D8C4914

P407

Q33289806-1FC9B4A7-08F9-4B70-94A6-4F7F214F6387

P478

Q33289806-61BB2409-86F7-4046-A737-641F0AF30965

P50

Q33289806-7522B209-558A-4648-81A3-61E7CDB9B047

Q33289806-C7053D8B-A902-430A-A69D-2388B0F03464

Q33289806-E3C7B0AE-ACBA-459B-9C96-8331302EADC9

P577

Q33289806-6C73BA92-216B-44A1-A277-8714CE224C19

P5875

Q33289806-3F623176-7AE6-4C79-A921-AEC420A85BBE

P6179

Q33289806-AD194FD9-2CEA-48CC-B409-9033FC12E9AF

P698

Q33289806-1F16FFFF-E769-4C63-B206-4AC553583D7E

P932

Q33289806-11D101C4-E4EE-4A0E-A758-92D36A76DF15

P356

1471-2407-7-119

P1433

P1476

A full scale comparative study ...... ls for use as cancer vaccines.

@en

P2093

Gunnar Kvalheim

http://www.w3.org/2001/XMLSchema#string

Hege Hammerstad

http://www.w3.org/2001/XMLSchema#string

Silvija Jarnjak-Jankovic

http://www.w3.org/2001/XMLSchema#string

Stein Saebøe-Larssen

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction.

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

Antigen uptake and presentation by dendritic leukocytes.

Proliferating dendritic cell progenitors in human blood.

Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells.

Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma.

Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34(+) blood progenitor cells.

P2888

1471-2407-7-119

P304

119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-7-119

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Silvija Jarnjak-Jankovic

Stein Saebøe-Larssen

Gustav Gaudernack

P577

2007-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6228669

http://www.w3.org/2001/XMLSchema#string

P6179

1027082040

http://www.w3.org/2001/XMLSchema#string

P698

17608923

http://www.w3.org/2001/XMLSchema#string

P932

1931601

http://www.w3.org/2001/XMLSchema#string